Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Edema 2Brain Neoplasms 2Brain Edema 2Astrocytoma 2

Interventions

Temozolomide 53Bevacizumab 45Radiotherapy 28Radiosurgery 21Carboplatin 14Erlotinib Hydrochloride 11Radiation 10pembrolizumab 9Magnetic Resonance Spectroscopy 9Etoposide 9Vorinostat 8Trastuzumab 8Irinotecan 8Sunitinib 7Sorafenib 7Radiotherapy, Intensity-Modulated 7Lomustine 7Lapatinib 7Capecitabine 7dabrafenib 6Ipilimumab 6Imatinib Mesylate 6Cyclophosphamide 6Sirolimus 5Hydroxyurea 5Everolimus 5Bortezomib 5temsirolimus 4cabozantinib 4binimetinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Brain Neoplasms × Corticotropin-Releasing Hormone × Clear all
NCT00088166 2014-08-13

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Celtic Pharma Development Services

Phase 3 Completed
200 enrolled 17 charts
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

NCT00226655 2012-08-31

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

Celtic Pharma Development Services

Phase 3 Completed
112 enrolled 8 charts
CNS

Astrocytoma, Brain Edema, Brain Neoplasms, Edema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡